The Cannabis Advisory

CBD News

CB1 receptor

STUDY: Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist

Written By

ABSTRACT: Rimonabant, the prototypic antagonist of cannabinoid CB1receptors, has been reported to have inverse agonist properties at higher concentrations, which may complicate its use as a tool for mechanistic evaluation of cannabinoid pharmacology. Consequently, recent synthesis efforts have concentrated on discovery of a neutral antagonist using a variety of structural ... Continue Reading

STUDY: Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic

Written By

ABSTRACT: The limited effectiveness of current therapies against Alzheimer’s disease (AD) highlights the need for intensifying research efforts devoted to developing new agents for preventing or retarding the disease process. During the last few years, targeting the endogenous cannabinoid system has emerged as a potential therapeutic approach to treat Alzheimer. The ... Continue Reading

STUDY: Cardiovascular Pharmacology of Cannabinoids

Written By

ABSTRACT: Cannabinoids and their synthetic and endogenous analogs affect a broad range of physiological functions, including cardiovascular variables, the most important component of their effect being profound hypotension. The mechanisms of the cardiovascular effects of cannabinoids in vivo are complex and may involve modulation of autonomic outflow in both the central and ... Continue Reading

STUDY: Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system

Written By

ABSTRACT: Nausea and vomiting (emesis) are important elements in defensive or protective responses that animals use to avoid ingestion or digestion of potentially harmful substances. However, these neurally-mediated responses are at times manifested as symptoms of disease and they are frequently observed as side-effects of a variety of medications, notably those used to ... Continue Reading

STUDY: Paranoid Schizophrenia is Characterized by Increased CB1 Receptor Binding in the Dorsolateral Prefrontal Cortex

Written By

ABSTRACT: A number of studies suggest a dysregulation of the endogenous cannabinoid system in schizophrenia (SCZ). In the present study, we examined cannabinoid CB1 receptor (CB1R) binding and mRNA expression in the dorsolateral prefrontal cortex (DLPFC) (Brodmann's area 46) of SCZ patients and controls, post-mortem. Receptor density was investigated using autoradiography ... Continue Reading

Contributing Authors

Send this to a friend